L. Elzi

Discipline

Economies et finances (2) Sociologie (1) Anthropologie biologique (1)

Type de document

Articles (23) Recensions (1)

Co-auteur

Date

Source

Mot-clé

cohorte (19) Swiss (18) thérapie (17) Treatment (17) Therapeutics (17) Human beings (15) Methods (14) Patients (14) Methods (14) Patients (14) virus (13) Immunodeficiency (12) Ci (Chinese poetry) (12) Confidence (12) risque (10) adulte (10) Risk (10) adulte (10) temps (durée) (8) Time (8) Older people (8) danger (7) Use (7) art (6) effet (6) âge (6) Art (6) Art (6) Cases (6) Rates (6)

Documents écrit par L. Elzi (23) | parle de L. Elzi (0)

Prevalence and Significance of Hypermetabolic Lymph Nodes Detected by 2-[18F]FDG PET/CT after COVID-19 Vaccination: A Systematic Review and a Meta-Analysis.
G. Treglia et al. (3 août 2021)
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis.
T. Turk et al. (12 sept. 2017)
Adverse events of raltegravir and dolutegravir.
L. Elzi et al. (24 août 2017)
Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study.
L. Elzi et al. (2016)
Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study : changes in treatment uptake and outcomes between 1991 and 2013
G. Wandeler et al. (2015)
Increases in condomless sex in the Swiss HIV Cohort Study.
R.D. Kouyos et al. (2015)
Obesity trends and body mass index changes after starting antiretroviral treatment : the Swiss HIV Cohort Study
B. Hasse et al. (2014)
AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to be.
V. Gisler et al. (2014)
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.
A.U. Scherrer et al. (2012)
Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens.
A.U. Scherrer et al. (2012)
Ageing with HIV: medication use and risk for potential drug-drug interactions.
C. Marzolini et al. (2011)
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.
R. Lubomirov et al. (2011)
Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB?) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection.
L. Elzi et al. (2011)
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.
A.U. Scherrer et al. (2011)
No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy.
M. Ortiz et al. (2011)
Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland.
A. Kenfak-Foguena et al. (2011)
Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia.
T. Ferry et al. (2010)
Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals.
M. Rotger et al. (2010)
Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study.
S. Franceschi et al. (2010)
Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
N. Khanna et al. (2009)
Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
S. Franceschi et al. (2008)
Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study
B. Ledergerber et al.
Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission
L. Elzi et al.